It can be nerve racking. Especially if your cost basis is
It can be nerve racking. Especially if your cost basis is over the $. I've gotten use to it (manipulation). Not saying I don't use stop loss here and there IF I think I need to.
The company has given no indication of giving anything up and the science is kicking butt.
Till otherwise, I'm accumulating.
You want to see a company in limbo (now with no CEO; CFO stepped in) trying to partner to pay for trials? Take a look at SYN. I think Leo not only has better science than SYN (BY A LONGSHOT!!!!) though we'll just have to see how long it takes for Leo to get that first deal. So there is a bit of fear out there.
Again, I'm accumulating.
Prurisol data pending. fear that it won't pass the mustard. I think it more than will.
Again, I'm accumulating.
$IPIX
I'll stop in a bit later if I can.
1
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Wells Fargo's Recent Adjustments on American Tower Corporation In a recent move, Wells Fargo has made notable adjustments regarding American Tower Corporation (NYSE: AMT). The financial institution has downgraded the company’s stock from Overweight to Equal Weight while also reducing its price target to $230, down from $245. This decision stems from certain...
Continue Reading
WeightWatchers Strengthens Leadership and Expands Health Initiatives WeightWatchers is making headlines as it completes a significant financial reorganization, enhancing its operational capabilities and leadership. With the appointment of respected figures in the health industry, including Dr. Kim Boyd as Chief Medical Officer, the Company aims to expand its services and...
Continue Reading
Unpacking the Short Interest for FactSet Research Systems FactSet Research Systems's short percent of float has seen a decline of 7.56% since its last report, reflecting a changing sentiment among traders. The recent data indicates that the company currently has 2.16 million shares sold short, equating to 6.48% of all its regular shares available for trading. Looking at...
Continue Reading
Investor Insights: Bausch + Lomb Faces Scrutiny Over Stock Drop Bausch + Lomb Corporation, known for its high-quality vision and eye health products, has recently come under fire as Pomerantz LLP initiates a probe on behalf of its investors. This legal investigation stems from potential securities fraud or other irregularities that may affect the company’s integrity and...
Continue Reading
EquipmentShare Faces Legal Storm Alright folks, plenty of us have been around the block long enough to know that when a new IPO gets hitched up to a lawsuit train, you better sit up and take notice. EquipmentShare.com, Inc. (NASDAQ:EQPT), a name that not too long ago was supposed to be a hotshot player in the cloud-based equipment rental game, is knee-deep in legal muck...
Continue Reading
